London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Neil, -
Found the problem.
My notes contain the text on the video-
"We also have a direct sales force that will be focusing"
What he says is different:
"We WILL also have a direct sales force that will be focusing"
I can only apologies for the misunderstanding.
It will soon be made clear what we have in the USA I believe, thanks for bringing the matter up.
B2HS2L, Don't agree, I've seen the video and Kevin is talking in the future tense. In fact Kevin starts the sentence before "In the future...."
In my opinion, at present there's no direct sales force within the USA, we'd have seen the vacancies advertised and we'd have come across the employed individuals upon linkedin. It would be madness to put a North America sales team in place without the approvals, a sales team to sell RUO and EUA products.
Any bid for the company would only have to be high enough for the majority of shareholders to agree.
I have no idea what the average share price average is but an offer of £5 per share would probably get through.
No room left, but yes Liz has moved on, but she was busy in South America for us.
neil, -
Kevin's "We also have a direct sales force that will be focussing on expanding our distributor network."
From:
August 2021 - Novacyt Investor Meeting. - Q&A
http://novacyt.com/wp-content/uploads/2021/09/Investor-meeting-QA-August-2021-ENG.pdf
6. How does the distribution network work? Novacyt’s sales force seems very strong in the UK,
with heavy recruitment, but how big/effective are the distributors in the rest of the world?
GM: As previously presented, we have a very well-established distributor network, with more than 400 distributors
currently. This distributor network is essential for our growth strategy going forward. The channel
represented approximately 35% of our business, without the DHSE contract, in the first half of the year. Its
geographical distribution is also very well balanced, with revenues in the Americas, including Latin America,
of approximately 30%; EMEA, which includes Europe, Middle East and Africa, with approximately 55% – of
which 25% is UK and Ireland – and in Asia we have 15% of our distributor business.
The indirect sales channel is one of our key enablers for our global presence. If we look into our direct sales,
it generated 65% of revenues, again without the DHSE contract, in the first half of 2021. As mentioned
during my presentation, a well-balanced sales channel mix will enable our future growth. Increasing our
market access is a key pillar of our commercial strategy in increasing our share of all of that customer base
and generating market share gains.
+++
Whilst the US direct sales team has only one product that has EUA to sell, Kevin is getting them to expand the network. Seems reasonable in the circumstances, but direct sales represents a bigger chunk of our income as stated above.
Also
Liz F.
Business Development - Latin America
Dates EmployedJan 2010 – Feb 2020
Employment Duration10 yrs 2 mos
LocationUnited Kingdom
Offered a part-time agreement to develop sales for the group focused on the Latin American Region. It allowed continuous development at GESS Technologies while also developing new business for Lab 21.
Key Accomplishments:
Sales Growth – Successfully closed one of the largest business the company had ever sold in single transaction. Led increase of annual sales of existing distributors network first established by Plasmatec. Led distributor selection and set payment terms and conditions.
Territory Expansion – Developed a sales and marketing strategy plan that identified new distributors in Mexico, Panama, Dominican Republic, Honduras, Guatemala, Colombia, Ecuador, Brazil, Uruguay, Bolivia, Peru and Chile.
Regulatory Compliance – Managed all technical documentation, certifications and contracts required to support local registration and meet local Ministry of Health requirements in each country for new distributors.
I don't believe that the direct sales force within the USA has materialised, if it had, there'd be evidence upon the likes of Linkedin. From what I could see, we employed two people within the USA, one of which was Liz, however Liz is now working for YGEN. Also, many of our products within the USA are for RUO, therefore would make no sense to employ a Sales team until such time that the FDA approvals for our products are in place.
Uggy, I can imagine DA was not happy with certain people doing certain jobs, and that would take time to sort out.
He has had 3 months to do that now, and some of the higher management changes have been observed on LinkedIn.
It's time for that to be formalised, - even if outsiders are on gardening leave awaiting a start at Novacyt.
USA, - do we have a direct sales team and what is it's performance.
I note in the 18.10.2021 video to support the virtual meeting of ASHG21 that Kevin Crittenton discussed USA sales and stated "We also have a direct sales force that will be focussing on expanding our distributor network." - so how big is it (10?), where is it situated, and what has been it's performance.
I agree, DA's refusal to engage with shareholders is quite disgraceful.
Lets hope DA does step up to ths plate. For a man with a sales & marketing background I find his refusal to engage with shareholders quite disgraceful.
Agree with the second part.
IMO if the board aren't interested in an offer or the sp, they will maintain the status quo.
Not expecting too much at the end of January in the way of fresh information, but they must update on IT-IS sales to TATA, and it's time for a video from DA, - nothing less will do.
Regardless of the RNS, YGEN share up only !%.
So a company constantly sending RNS has less impact on one that sends them sparingly.
Come on David, just one would be nice.
I would have thought those venturing a bid will look at the current share price as a guide to any bid, surely it would be in the companys interest to have a higher share price, apart from that surely it's illegal to withold information that might increase the share price
_Mr_Big -
"What really bothers me, is why do they not care about IIs. Still no II support despite cash in bank, revenues,
profits and strong R&D."
I think the answer is confidence.
The BoD are confident:
1 they won't need to raise cash in the forseable future.
2 they know how much the business is worth, and could demonstrate it's value to shareholders should a bid arrive
in the post / be made public.
3 they know they have taken into account the financial problems created by the DHSC dispute, and are confident
they will win in the end.
So they just plough on with the plan to create a Mid-Cap status company, the difference being they know what
it's worth, shareholders don't, and this way - neither do those venturing a bid.
What's important IMO is that should it be necessary, shareholder value will be revealed, but the bid will have to be good to match the companies valuation of the R&D and Informatics teams.
To be more precise - they don't give a damn about short term sp as they don't need to raise cash any time soon.
Nobody ever cares about PIs.
What really bothers me, is why do they not care about IIs. Still no II support despite cash in bank, revenues, profits and strong R&D.
You know full well he is rugby fan xxx
Valju they do not play the game because they don’t give a dam about shareholders.
I agree with the rant.
I guarantee PI’s will take this BOD and CEO down by the time of the next AGM if they haven’t sorted things out.
People will get organised.
All it takes is somebody to setup a very simple Novacyt shareholders website. With it all being owned by PI’s we are in the driving seat. Would have been a great task for Porky or whatever his latest name is on here.
Is he still active on twitter?
Nice rant Val lol
Morning Wilson, but was it rns'd at the time, by NOVA ???
Sorry, but this is still Aim, and the way Co's improve sp wise is normally, by positive Rns's as GM proved in the beginning!
They cannot play Mid Cap, just because they made a few quid and dont need PI's right now!
Sucks of an agenda imo and until it is proved different, the trust for me has gone in the BoD
Patience, yes I have patience, and I have waited added, reduced overall average, etc. been positive on many occasion and now feel negative at present and before the clever dicks, decide to comment about selling up and moving on, I DONT need to, infact if the lot went tits up, it would affect my life other than ****ing me off a tad.
But what I dont understand is why the BoD dont play the Aim (positive rns) game, the same as all others, when they probably have more reason to shout from the rooftops, what they have done, are now doing and have so far achieved! WHY WHy WHY ?
all imo
Rants over :)
Hi Wilson .
You are correct , no links between us anymore . There was a manufacturing agreement for Ygen to make our tests but It never came to fruition .
Valju it was a manufacturing agreement which I think some will say has long lapsed.
http://novacyt.com/wp-content/uploads/2020/03/Novacyt-YourGene-PR-ENGLISH-25.03.20-final.pdf
Ygen are showing the markets a post covid plan regarding us deals with oncology and NIPT (pre natal testing ).
This is what Novacyt needs to do . Apologies for posting here although I think we have a few joint holders and comparisons with EKF and YGEN exist with Novacyt.
That and the fact NCYT are currently giving us Feck all to discuss here .
Valju? A Nova company?
This is sp affecting!
A Nova group Co, signs strategic partnership agreement in USA biggest market there is?
Yet all Nova do is tweet, about a Jolly & Marketing Sales event in Dubai!
BoD are deliberately attempting to keep sp restrained / low!
Very bad ethics imo
Why is the question!
@fca need to ask them serious questions about how much SP affecting info they SHOULD have released ! DA = Puppet as I see it!
Meanwhile on a board where the company actually RNS . Ygen is partnering with EKF.
EKF has been compared to Novacyt many times on this board in terms of valuations .
Come on Novacyt . Let us know what you are up to .
Yourgene Health plc
("Yourgene" or the "Company")
US partnership with EKF Diagnostics for NIPT and additional genomic tests
Collaboration with EKF Diagnostics to use its accredited US laboratories for NIPT and Oncology testing
Manchester, UK - 18 January 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has signed a strategic partnership agreement with EKF Diagnostics Holdings plc ("EKF", AIM: EKF), a point-of-care business with accredited laboratory testing capabilities in the US, whereby EKF will offer an NIPT service to the US market based on Yourgene's proprietary non-invasive prenatal technology for an initial 5-year period.